Deloitte February 12, 2021

Exploring lessons learned from the technology sector

What will health look like in 2040? And how might technology-driven convergence help accelerate innovation in the life sciences? Discover how life sciences organizations can leverage insights from other industries who have converged to capitalize and power innovation, thrive amid uncertainty, and leapfrog the standard of care available to most patients.

Reimagining life sciences business models by 2040

Health in 2040 will be a world apart from what we have now. Our future of biopharma and future of medtech predictions project accelerated change across multiple industry use cases and the potential for completely disrupted business models. In our report, we outline ways for...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech, Technology
Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry

Share This Article